Difference between revisions of "Ziv-aflibercept (Zaltrap)"
m |
m |
||
| Line 14: | Line 14: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * 8/31/2012: Initial FDA approval | + | * 8/31/2012: Initial FDA approval in combination with [[Fluorouracil (5-FU) | 5-fluorouracil]], [[Folinic acid (Leucovorin) | leucovorin]], [[Irinotecan (Camptosar) | irinotecan]] - ([[Colon_cancer#FOLFIRI_.26_Ziv-aflibercept_.28Zaltrap.29 | FOLFIRI]]), is indicated for patients with metastatic [[:Category:Colorectal_cancers|colorectal cancer]] (mCRC) that is resistant to or has progressed following an [[Regimen_classes#Oxaliplatin-based_regimen | oxaliplatin-containing regimen]]. |
==Also known as== | ==Also known as== | ||
Revision as of 14:46, 3 February 2020
General information
Class/mechanism: Recombinant fusion protein between the Fc portion of human IgG1 and the extracellular domains of VEGF receptor 1 & 2 (VEGFR 1 & VEGFR 2), which binds VEGF-A and VEGF-B (vascular endothelial growth factor), as well as PGF (placental growth factor). By binding to and inhibiting these angiogenic growth factors, their neovascular activity, and vascular permeability, ziv-aflibercept inhibits tumor angiogenesis.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Brief patient counseling information is available in the Ziv-aflibercept (Zaltrap) package insert.[1]
- Ziv-aflibercept (Zaltrap) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 8/31/2012: Initial FDA approval in combination with 5-fluorouracil, leucovorin, irinotecan - ( FOLFIRI), is indicated for patients with metastatic colorectal cancer (mCRC) that is resistant to or has progressed following an oxaliplatin-containing regimen.
Also known as
- Generic names: aflibercept, VEGF trap
- Brand names: Eylea, Zaltrap